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Available online 27 September 2013Abstract Pancreatic tumors contain cancer stem cells highly resistant to chemotherapy. The identification of therapies that
can eliminate this population of cells might provide with more effective treatments. In the current work we evaluated the
potential of oncolytic adenoviruses to act against pancreatic cancer stem cells (PCSC). PCSC from two patient-derived
xenograft models were isolated from orthotopic pancreatic tumors treated with saline, or with the chemotherapeutic agent
gemcitabine. An enrichment in the number of PCSC expressing the cell surface marker CD133 and a marked enhancement on
tumorsphere formation was observed in gemcitabine treated tumors. No significant increase in the CD44, CD24, and
epithelial-specific antigen (ESA) positive cells was observed. Neoplastic sphere-forming cells were susceptible to adenoviral
infection and exposure to oncolytic adenoviruses resulted in elevated cytotoxicity with both Adwt and the tumor specific
AduPARE1A adenovirus. In vivo, intravenous administration of a single dose of AduPARE1A in human-derived pancreatic
xenografts led to a remarkable anti-tumor effect. In contrast to gemcitabine AduPARE1A treatment did not result in PCSC
enrichment. No enrichment on tumorspheres neither on the CD133+ population was detected. Therefore our data provide
evidences of the relevance of uPAR-controlled oncolytic adenoviruses for the elimination of pancreatic cancer stem cells.
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Open access unIntroduction
Pancreatic ductal adenocarcinoma remains one of the most
aggressive and devastating tumor malignancies with an
overall 5-year survival rate of less than 5% (Kern et al.,
2011). The only potentially curative treatment is the
complete surgical resection of the tumor. Nevertheless,
even after the complete tumor resection disease progression
is often described. Under such circumstances identification
of therapies that can target both bulk cancer cells and tumorder the CC BY-NC-ND license.
2 L. Sobrevals et al.initiating cells is important in improving pancreatic cancer
treatment.
Recent work in pancreatic cancer biology has identified a
distinct subpopulation of cells termed cancer stem cell (CSC)
that may represent an integral part of the development and
perpetuation of the tumor. Cells bearing stem cell properties
from human adenocarcinoma have been defined by the
expression of specific cellular markers, their self-renewal
capacity, differentiation ability and in vivo tumorigenicity. In
pancreatic cancer the subpopulations of CD44+/CD24+/ESA+
(Bednar and Simeone, 2009; Li et al., 2007, 2009); CD133+
(Hermann et al., 2007; Lonardo et al., 2011) or ALDH1+
(Rasheed et al., 2010) have been identified to fulfill all these
criteria. Emerging evidences indicate that pancreatic cancer
stem cells are resistant to chemotherapy and radiation
suggesting that such cells may be the source of the virtual
relapse of pancreatic cancer (Balic et al., 2012). Therapeutic
modalities leading to the elimination of CSC are an opportu-
nity for the effective treatment of pancreatic cancer.
Oncolytic adenoviruses are very promising anticancer
agents. They are engineered to specifically target, replicate
in and destroy cancer cells (Aghi and Martuza, 2005; Fillat et
al., 2010; Friedman et al., 2012; Short and Curiel, 2009).
Oncolytic adenoviruses targeting the abnormal Rb/p16
pathway have been shown to be able to kill brain and breast
cancer initiating cells (Eriksson et al., 2007; Jiang et al.,
2008). Furthermore, oncolytic adenoviruses driven by the
tissue-specific promoters multidrug resistance (mdr) and
cyclo-oxygenase 2 (Cox-2) have been shown to be active in
breast cancer initiating cells (Bauerschmitz et al., 2008).
Recent studies in small cell lung cancer identified cells with
stem-like properties being positive for uPAR gene expression
(Gutova et al., 2007; Qiu et al., 2012). As we have previously
shown uPAR-controlled adenoviruses are highly active in
pancreatic cancer cell lines and exert strong antitumor and
anti-metastatic effects in xenografts (Huch et al., 2009). In
the current study we sought to explore the ability of uPAR
controlled oncolytic adenoviruses to act against pancreatic
CSC (PCSC). We used two primary patient xenograft models to
characterize pancreatic cancer stem cells and determined the
effects of AduPARE1A on PCSC cells and compared to those of
gemcitabine, the most common chemotherapeutic agent used
in pancreatic cancer treatment. We found that PCSC are
susceptible to adenoviral transduction and are sensitive to
adenovirus mediated cell death by AduPARE1A oncolytic
adenovirus. In vivo treatment with a single AduPARE1A viral
administration triggered significant reduction in tumor pro-
gression. In contrast to gemcitabine treatment, AduPARE1A
did not increase the PCSC population. Thus, our results show
that AduPARE1A shows efficacy in suppressing pancreatic
cancer stem cells and could be a beneficial therapy to treat
pancreatic cancer patients.
Materials and methods
Preparation of single-cell suspensions from human
PDAC tumors
Human CP15 and CP13 adenocarcinoma surgical samples were
obtained and implanted into the pancreas of immunodeficient
mice as previously described (Perez-Torras et al., 2011). CP15and CP13 were selected from a tumor platform of 11 PDAC
specimens. Tumorgrafts retained original morphology of the
human primary tumor at the generations used in the current
study. To obtain single-cell suspensions, CP15 and CP13 tumor
fragments, from fresh or frozen tissue, were cut into small
pieces and minced completely and then an enzymatic
dissociation was applied using 200 U/ml ultrapure collagenase
IV (Sigma, Freehold, NJ) in DMEM–F12 medium and incubated
at 37 °C for 2 to 3 h. The specimens were further mechani-
cally dissociated every 15 to 20 min by pipetting. At the end of
the incubation, cell suspension was washed twice with DMEM–
F12 supplemented with 10% of heat inactivated fetal bovine
serum (FBS). Then, cells were filtered through a 70-μm filter,
collected in a fresh 50-ml conical tube and adjusted to a final
volume of 15 ml per tube. In order to deplete death cells or
tissue debris, tumor cell suspension was separated by density
centrifugation using Ficoll-Paque Plus. Cell suspension and
Ficoll layers were centrifuged at 500 ×g for 30 min with the
brakes turned off. Dissociated cells were transferred to a fresh
50-ml conical tube. Fresh DMEM–F12 supplemented with 10%
FBSwas added to the cell suspension to dilute it 1:3. Cells were
filtered through a 40-μm filter and collected by centrifugation
at 450 ×g for 10 min. The cell pellet was resuspended in 1 ml of
DMEM–F12 supplemented with 0.4% FBS or in PBS/2% BSA
according to the procedure.
Human pancreatic tumorsphere formation and
culture conditions
To generate tumorspheres, single-cell suspensions from CP15
and CP13 tumors were cultured in DMEM–F12 supplemented
with 0.4% FBS, Gibco, Life Technologies), 2 mM L-glutamine
(Gibco, Life Technologies), 10 U/ml penicillin and 10 μg/ml
streptomycin (Gibco, Life technologies), 20 μg/ml gentamicin
(Gibco, Life Technologies), B27 1× (Gibco, Life Technologies),
5 μg/ml insulin (insulin solution from bovine pancreas, I0516
Sigma-Aldrich), 20 ng/ml of recombinant human epidermal
growth factor (HuEGF, Invitrogene, Life Technologies), and
20 ng/ml basic fibroblast growth factors (bFGF, BD Bioscience)
at 37 °C and plated onto 24multiwell plates (Lab-Tek, Nunc) at
a density of 5.000–10.000 cells/well. These plates were
previously coated with 10 mg/ml Poly-HEMA (Sigma-Aldrich).
The mediumwas designated as tumor-initiating cell medium or
TIC medium. Cells were cultured in TIC medium for at least
1–2 weeks or until the appearance of non-adherent spherical
clusters. Spheres were enzymatically dissociated (Trypsin-
EDTA), and sub-cultured in TIC medium for several passages
before initiating the experimental assays. To allow differenti-
ation, dissociated sphere cells were plated under standard
medium supplemented with 10% FBS.
Flow cytometry analysis
Cells were resuspended in PBS 2% BSA and incubated for
30–45 min at room temperature with the corresponding
antibodies. Then samples were washed twice with PBS 2%
BSA, resuspended in PBS 2% BSA containing DAPI (4′,6-
diamidino-2-phenylindole, Sigma) at 1 μg/ml and incubated
for 15 min on ice. The antibodies used were: anti-CD133-APC
(clone CD133/1 (AC133), Miltenyi Biotech), APC-H7 mouse
anti-human CD44 (clone G44-26 (also known as C26), BD
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Pharmingen™), PerCP-Cy5.5mouse anti-human CD326 (EpCAM)
(clone EBA-1, BD Pharmingen™), anti-H2K-FITC (H100-27.R55.
Miltenyi Biotech) and appropriate isotype-matched control
antibodies. In all the experiments using human xenograft
tissue, infiltrating mouse cells were eliminated by discarding
H2K (mouse histocompatibility class I) cells during flow
cytometry, as previously described (Li et al., 2007). Dead
cells were eliminated by using the viability dye DAPI. Flow
cytometry was done using a BD™ LSR II flow cytometer or a BD
FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, USA). Data
were analyzed with CELLQuest Pro or FACSDiva software
(Becton Dickinson). GFP-positive cells were quantified by flow
cytometry (BD™ LRS II).
Adenoviruses
AduPARE1A and AdCMVGFPLuc have been previously described
(Alemany and Curiel, 2001; Huch et al., 2009). Adwt, the
wild-type adenovirus, was obtained from the ATCC (Manassas,
VA). Replication-defective viruses and Adwt were propagated
in HEK293 cells, and the oncolytic AduPARE1A virus was
amplified in RWP1 cells. All viruses were purified by standard
cesium chloride banding. The physical particle concentration
(vp/ml) was determined by optical density reading (OD260) and
the plaque forming units (pfu/ml) were determined on HEK293
cells by the anti-hexon staining-based method (Cascante et
al., 2007). AduPARE1A and Adwt presented an equal ratio of
vp and pfu.
In vitro cytotoxicity assays
Cytotoxicity assays were performed by seeding 3.000 tumor
initiating suspension cells per well in 48-well poly-HEMA coated
plates and cultured in TICM. Cells were infected with serial
dilutions of AduPARE1A and Ad5wt starting from 1 × 105 vp/cell
to 0.001 vp/cell. Seven days later, plates were centrifuged and
washed with PBS. Cell viability was measured using the MTT
colorimetric assay. ID50 values were estimated from dose–
response curves by standard nonlinear regression (GraFit;
Erithacus Software, Horley, UK), using an adaptedHill equation.
RT-PCR
Total RNA from tumors and spheres was isolated using RNeasy
(Qiagen, Hilden, Germany) following the manufacturer's
instructions. Samples were treated with DNAse (DNAfree,
Ambion). Reverse transcription reaction was performed to
generate cDNA using a Retroscript RT kit (Ambion). The
obtained cDNA was PCR amplified with uPAR gene specific
primers (Fwd: 5′-GCCTTACCGAGGTTGTGTGT-3′; Rv: 5′-CAT
CCAGGCACTGTTCTTCA-3′). RT-PCR results were confirmed by
two independent RT-PCR amplifications. E1A expression and
uPAR expression were determined by quantitative PCR (Via™
7, Applied Biosystem) using SYBR Green reagent and specific
primers (E1A: Fwd:5′-ATCGAAGAGGTACTGGCTGA-3′; Rv:5′-
CCTCCGGTGATAATGACAAG-3′; uPAR: Fwd: 5′-GCCTTACCGA
GGTTGTGTGT-3′; Rv:5′-CATCCAGGCACTGTTCTTCA-3′). β-Actin
gene was used to normalize expression. β-Actin specific primers:
(Fwd: 5′-CTGGAACGGTGAAGGTGACA-3′; Rv: 5′-GGGAGAGGAC
TGGGCCATT-3′).Orthotopic human pancreatic cancer xenografts
Orthotopic human pancreatic cancer xenografts were gen-
erated as previously described (Jose et al., 2012; Kim et al.,
2009). Briefly, a laparotomy incision in the left dorsal side of
the mouse was performed to expose the spleen and the
pancreas. Then, 3 × 105 CP15 or 4 × 105 CP13 tumor cells
were injected into the pancreas of 8-week-old male athymic
nude mice (Harlan Interfauna Iberica), in a final volume of
50 μl. Abdominal muscle layer was closed with interrupted
suture and the overlying skin was closed using Autoclips®
(Stoelting Europe). Animals were randomly divided in two
groups: saline, and AduPARE1A. Treatments were initiated
when tumors reached a tumor volume ranging from 60 to
100 mm3, measured by dorso lateral palpation. A single
dose of AduPARE1A (5 x 1010 vp/mouse) was intravenously
injected. To assess the effect of the treatments, animals were
euthanized 30 days after the initiation of the treatments.
Pancreatic tumors were fractioned and frozen in OCT for
histological analysis (Akura Finetek, Zoeterwoude) or in liquid
nitrogen for molecular studies.
Orthotopic xenografts from pancreatic tumorspheres
were generated as previously described (Jose et al., 2012;
Kim et al., 2009) by the inoculation in the pancreas of single
cell suspension after tumorsphere trypsin digestion.Tumor growth studies
Pancreatic tumors were measured at the end of the
experiments, and volumes were calculated according to
the formula V (mm3) = 0.4 · (larger diameter · smaller
diameter2). Animal procedures met the guidelines of
European Community Directive 86/609/EEC and were ap-
proved by the Local Ethical Committee.Immunohistochemistry
Paraformaldehyde-fixed paraffin embedded tumors were
obtained and 3 μm paraffin embedded sections were stained
with haematoxylin–eosin for morphological analysis. Immu-
nofluorescence was performed in frozen tissue sections
embedded in OCT by incubating with the anti-adenovirus
2/5 E1A antibody (sc-430, Santa Cruz Biotechnology Inc.).
Alexa Fluor 633-labeled goat anti-rabbit IgG antibody
(Molecular Probes, Life Technologies) was used as a
secondary antibody. The nuclei were counterstained with
5 μg/ml bis-benzimide (Hoechst 33342; Sigma) and visualized
under a fluorescent microscope (Nikon Eclipse 50i, Spain). The
fluorescent images were captured using a digital camera
(CoolCube1, MetaSystems).Statistical analysis
Data are expressed as mean ± SEM. Statistical significance
was estimated with nonparametric U-Mann Whitney test or
the parametrical t-test. A P-value of b0.05 was considered
significant (*). Statistical analyses were carried out with
Prism (version 5; GraphPad software).
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Characterization of cancer stem cells from human
pancreatic tumorsAs a first step towards the evaluation of the efficacy of
oncolytic adenoviruses to eliminate cancer initiating cells in
pancreatic tumors we characterized pancreatic cancer stem
cells (PCSC) in patient samples derived from early passage
human xenograft adenocarcinomas perpetuated in the pan-
creas and never expanded in vitro and designated as CP15 and
CP13, (Table 1) (Perez-Torras et al., 2011). The expression of
the cell surface markers CD133, and the combination of CD24,
CD44 and ESA previously identified as characteristic of PCSC
were analyzed by flow cytometry (Hermann et al., 2007; Li et
al., 2007). Because an enrichment of CSC has been reported to
occur upon chemotherapeutic treatments (Mueller et al.,
2009; Hindriksen and Bijlsma, 2012), the study was performed
in untreated xenografts and in xenografts from mice that
received a weekly dose of gemcitabine (160 mg/kg) for five
weeks (Fig. 1A). Gemcitabine treatment slowed tumor growth
progression in both CP15 and CP13 models although statisti-
cally significant effects were only observed in CP15 tumors
(Fig. 1B). Two weeks after the last gemcitabine dose stem cell
markers were analyzed. Flow cytometric quantification of
CD133 in dissociated tumor xenografts revealed noticeable
differences in the two tumors, CP15 presented 37% of cells
positive for the CD133 marker whereas 61% of CD133+ cells
were detected in CP13. A significant increase in the number of
CD133+ cells was observed in both CP15 and CP13 tumors upon
treatment with gemcitabine (Fig. 1C). When examining the
expression of CD24 CD44 and ESA cell surface marker
combination, 0.6% and 1.1% of cells expressed the CD24+CD44+
ESA+ combination in CP15 and CP13 tumors respectively.
Gemcitabine treatment showed a tendency to increase the
frequency of the CD24+CD44+ ESA+ population in both CP15 and
CP13 tumors (Fig. 1C). These data show that xenografts from
CP15 and CP13 patient samples express cell surface markers of
PCSC that are enriched upon a gemcitabine treatment.
Another well defining trait of cancer stem cells is their
ability to grow in vitro as anchorage-independent colonies
termed tumorspheres. In the current work we evaluated the
capacity of isolated cells from CP15 and CP13 xenografts to
grow as spheres and we measured the number and size of the
spheres after the first and the fifth passage. Both tumors were
successfully expanded to form tumorspheres and stably
propagated for at least 20 passages. Comparing features in
the tumorspheres of the two tumors, no differences were
observed in the size of tumorspheres although a higherTable 1 Patient tumor data.
Model Tumor
staging
Nodal
invasion
Perineural
invasion
Vascular
invasion
Metastatic
recurrence
CP13 T2N1 2/21 1 0 LFU
CP15 T3N1 15/28 1 1 Lymph nod
liver, sup
LFU: lost follow-up.number of spheres were observed in CP13 both in the first
and the fifth passage. Consistent with an enrichment of PCSC
upon gemcitabine treatment, the number and size of spheres
were larger in tumorspheres expanded from gemcitabine
treated xenografts. Differences were more remarkable in
CP-15 tumors (3.8-fold increase in sphere number, 6.3-fold
increase in the sphere size) (Fig. 2A). To further analyze if the
tumorspheres exhibited the properties of stem cells we tested
for their capacity to differentiate and to recapitulate the
phenotype of the original tumor. Tumorspheres plated in
standard medium displayed an epithelial phenotype typical of
pancreatic cancer cell lines (Fig. 2B). Of notice the injection
of single cell suspensions of tumorspheres into the pancreas of
immunodeficient mice generated tumors that histologically
resemble CP15 and CP13 patients' primary tumors with an
early passage in nude mice (Fig. 2C).
Targeting cancer initiating cells with oncolytic
adenoviruses
We tested the capacity of adenoviruses to transduce pancreatic
cancer stem cells. Tumorspheres from CP15 and CP13 xeno-
grafts were infected with AdCMVGFPLuc reporter adenovirus
and GFP expression was analyzed at different time-points. GFP
expression was already evident at 24 h post-transduction and
three days later more than 80% of the cells were positive for
GFP (Supplementary Fig. 1). To evaluate the sensitivity of PCSC
to adenoviral mediated lytic cell death, tumorspheres were
incubated in the presence of different viral doses of wild type
adenovirus (Adwt) and the AduPARE1A oncolytic adenovirus. A
substantial cell killing effect was observed in tumorspheres
after Adwt and AduPARE1A infection showing similar cytotox-
icity in CP15 (ID50: 104 ± 15.42 Adwt, 108 ± 15.01 AduPARE1A).
CP13 tumorspheres displayed higher sensitivity to adenoviral
cytolysis (ID50: 71.72 ± 14.7 Adwt, 55.19 ± 7.74 AduPARE1A)
(Fig. 3A). The increased sensitivity in CP13 vs CP15 was of
2.0-fold in AduPARE1A infected cells. This was in line with an
increased expression of the uPAR gene in CP13 tumorspheres
(Fig. 3B).
AduPARE1A oncolytic adenovirus treatment does
not spare pancreatic cancer stem cells
To test the effect of AduPARE1A therapy in a clinically
relevant setting, a single dose of AduPARE1A 5 × 1010 vp/
mice was i.v. injected into mice bearing CP15 or CP13
tumors in the pancreas (Fig. 4A). Tumor volume was
measured at the end of the experiment on day 30 after
treatment was initiated. AduPARE1A treatment significantlyHistological
features
k-Ras
codon 12
p16
loss
p53 exons
4 to 9
Well-defined glands Yes Yes Exon 5
es,
rarenal
Irregular glandular
pattern
Yes Yes wt
Figure 1 Analysis of pancreatic cancer stem cell markers in CP15 and CP13 patients derived xenografts treated with
gemcitabine. A) Schematic representation of the treatment protocol. B) Analysis of the pancreatic tumor volumes (mm3) 6 weeks
after treatment was initiated (n = 7, CP15; n = 4, CP13). C) Flow cytometry quantification of CD133 cancer stem cell marker (left)
and the percentage of CD24 CD44 ESA positive cells (right) in dissociated treated tumor xenografts (n = 4). *p b 0.05, **p b 0.01.
5uPAR-controlled oncolytic adenoviruses eliminate cancer stem cellsinhibited both CP15 and CP13 tumor growths (Fig. 4B).
Evidence of viral replication was observed in treated tumors
as shown by the expression of E1A (Figs. 5C, D). Current
observations were limited to 30-days post-treatment due to
the presence of life-threatening tumors in the CP15 control
group. However, the detection of E1A gene expression in
treated tumors suggests that AduPARE1A antitumoral effects
could be more extensive if followed long term.
Having shown that gemcitabine treatment significantly
increased the percentage of CD133+ cells and the number and
size of tumorspheres from CP15 and CP13 treated tumors
(Figs. 1C, 2A), we determined the effects of AduPARE1A
treatment on the content of CD133+ cells and in tumorsphere
formation capacity. Interestingly, in contrast to gemcitabine
we did not identify any enrichment in the CD133+ cell
population neither in CP15 nor in CP13 (Fig. 5A). Moreover
AduPARE1A treated tumors showed a tendency to form less
tumorspheres than saline injected tumors in CP15 and a
significant smaller proportion of tumorspheres were formed in
CP13 treated tumors, at the passage analyzed (Fig. 5B).These data indicate that AduPARE1A triggers a strong
antitumoral response in pancreatic tumors and does not
enrich tumors on cancer stem cells.Discussion
Recent studies in cancer therapy favor the idea that the
disconnection between response rates and overall survival
may rely in the failure to effectively targeting CSC popula-
tions. Furthermore survival of these long-lived cells in the
presence of toxic compounds might facilitate for additional
mutations and increased resistance. In the present study we
have characterized PCSC from two patient-derived tumors and
shown that, although gemcitabine treatment induced partial
antitumor response, it leads to an increase in cells showing
CSC-like properties. In contrast, a therapeutic approach based
on the single intravenous administration of AduPARE1A
oncolytic adenovirus triggered remarkable anticancer effects
with no increase in the PCSC pool.
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Figure 3 In vitro cytotoxic effects of AduPARE1A oncolytic adenovirus in CP15 and CP13 tumorspheres. A) Schematic representation
of AduPARE1A and Adwt adenoviruses. MTT viability assay of CP15 (left) and CP13 (right) tumorspheres. A total of 3 × 103 cells/well
were plated in triplicate and infected with a dose range of 10−3 to 105 MOIs of Ad5wt or AduPARE1A. Cell viability was measured
7 days later and is expressed as the percentage of absorbance of treated wells compared with that of mock-infected cultures. Dose–
response curves and ID50 values were obtained by a standard no linear model based on the Hill equation. Data show a representative
experiment (n = 3). B) RT-PCR analysis of uPAR gene expression in CP15 and CP13 tumors and tumorspheres. β-Actin was used as
control for gene expression. Representative images and qRT-PCR.
7uPAR-controlled oncolytic adenoviruses eliminate cancer stem cellsIn agreement with previous observations we demonstrate an
enrichment in the CD133 population by gemcitabine treat-
ment, but not in the CD24, CD44, and ESA positive-cells,
suggesting that cancer stem cell chemoresistance, at least
with gemcitabine, might differentially affect the PCSC rep-
ertoire (Mueller et al., 2009; Venkatesha et al., 2012).
Gemcitabine treatment also increased the number of neo-
plastic sphere-forming cells and the size of the tumorspheres.
To validate the tumorigenic potential of tumorspheres we
demonstrate that the tumorspheres injected directly into the
mouse pancreatic tail result in tumor formation thatFigure 2 Analysis of tumorspheres from CP15 and CP13 patien
tumorspheres from CP15 and CP13 treated tumors formed from
Quantification (number) and volume (mm3) of tumorspheres formed
graphics) (n = 6). B) Images of CP15 and CP13 tumorspheres plated
staining of pancreatic tissue sections from CP15 and CP13 xeno
tumorspheres injected into the pancreas of immunodeficient mice (histologically resemble the morphology of an early passage
patient derived xenograft. These results support that
tumorsphere derived from CP15 and CP13 tumors retain the
features of tumor initiating cells in the pancreatic niche. All
together, these suggest that gemcitabine treatment enriches
in neoplastic cells with features of PCSC, in both CP15 and
CP13 tumors.
Oncolytic adenoviruses seem like ideal candidates to target
cancer initiating cells because they are cytotoxic and are not
subject to the typical mechanisms of drug resistance, such as
drug efflux pumps and defective apoptotic signaling. Indeed,t derived xenografts treated with gemcitabine. A) Images of
isolated cells that grew as anchorage-independent colonies.
from the CP13 and CP15 treated tumors at passages 1 and 5 (bar
in TIC medium or standard medium. C) Hematoxylin and eosin
grafts (left) or from CP15 (n = 3) and CP13 (n = 3) isolated
right). Scale bars 100 μm. *p b 0.05, **p b 0.01.
Figure 4 In vivo antitumor effects of AduPARE1A oncolytic adenovirus in CP15 and CP13 orthotopic tumors. A) Schematic
representation of the treatment protocol applied in orthotopic tumors derived from CP15 or CP13 single cell suspension of pancreatic
xenograft. AduPARE1A (5 x 1010 vp) or saline solution was intravenously administered to mice bearing CP15 or CP13 tumors in the
pancreas (n = 12, n = 7) or (n = 8, n = 8) respectively. B) Pancreatic tumor volumes (mm3) in saline and treated tumors 30 days after
virus injection are plotted as indicators of antitumor effect. C) qPCR analysis of adenoviral E1A gene expression in RT-PCR samples
from CP15 treated tumors. β-Actin was used as reference gene for normalization (n = 4). D) Anti-E1A immunofluorescence of CP15
tumors 30 days after i.v. administration of AduPARE1A (5 x 1010 vp) or saline solution. Two tumors of each group are shown.
*p b 0.05, **p b 0.01, ***p b 0.005.
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suggest that they may be effective against CSC (Alonso et al.,
2012; Bauerschmitz et al., 2008; Jiang et al., 2007). These
viruses are often generated on the basis of its tumor selectivity
to improve control of viral replication, resulting in diminished
toxicity. The use of tissue specific promoters preventing the
expression of E1A in non-target tissues is a useful strategy.
Here we show that uPAR promoter controlled adenovi-
ruses are able to kill neoplastic-sphere forming cells in vitro
with a similar or even with higher efficacy than wild typeadenoviruses. This is consistent with the observation that
these cells endogenously express the uPAR gene, suggesting
that the transcription factors acting on the regulatory
sequences of the uPAR gene are present in the target cells
and can activate the uPAR promoter. Importantly in vivo,
AduPARE1A treated tumors were much smaller than
mock-treated tumors, and had a similar proportion of CD133+
cells, and a smaller capacity to generate tumorspheres. This is
in contrast to what was observed in gemcitabine treated
tumors, where we observed an enrichment in the CD133
Figure 5 Analysis of pancreatic cancer stem cell features in CP15 and CP13 patient derived xenografts treated with AduPARE1A. A) Flow
cytometry quantification of CD133 positive cells in CP15 andCP13 tumors, 30 days after i.v. administration of AduPARE1A (5 x 1010 vp) or saline
solution (n = 6). B) Quantification of the number of tumorspheres grown as anchorage-independent colonies from CP15 and CP13 saline (n = 7)
and treated tumors (n = 7, n = 6) respectively 22 days after plating. CP15 tumorsphere representative images (right). Scale bars 100 μm.
9uPAR-controlled oncolytic adenoviruses eliminate cancer stem cellspopulation and an increase in tumorsphere number and
size. The fact that the in vivo effects of AduPARE1A
treatment on the CP15 and CP13 PCSC population showed
decreased sphere formation but no significant changes in
the percentage of CD133+ cells may indicate that addi-
tional PCSC present in tumorspheres, not detected by
CD133 positivity, would be sensitive to AduPARE1A treat-
ment. This highlights the need to investigate for additional
PCSC cellular markers as better predictors of AduPARE1A
response.
Nevertheless, our data suggest that AduPARE1A might
be able to kill PCSC in vivo, similarly to what was seen in
vitro and this can be appealing for pancreatic cancer
treatment. Interestingly, a subpopulation of uPAR posi-
tive cells has been identified in small cell lung cancer
cell lines, derived from lung and from bone marrow and
brain metastasis, which possess multi-drug resistance and
clonogenic activity (Gutova et al., 2007). uPAR positive
cells identified in the small cell lung cancer H466 were
capable of forming spheres and efficiently formed trans-
plantable tumors (Qiu et al., 2012). uPAR signaling has
also been reported to induce cancer stem cell like prop-
erties in breast cancer cells (Jo et al., 2010). Recently, it
has been shown that uPAR is important in the mainte-
nance of stem cells and is highly expressed in glioma
initiating cells. The regulation of malignant stem-cell
renewal was proposed to be through the activation of
several components of the hedgehog pathway (Gopinathet al., 2013). Moreover, a recent study provides evi-
dences of mutual regulation mechanisms among uPAR
and beta-catenin signaling in cancer stemness in medullo-
blastoma (Asuthkar et al., 2012). Although there are no
specific data on uPAR signaling in pancreatic cancer stem
cells, in the present work we show that tumorspheres
from both CP15 and CP13 tumors highly express the uPAR
gene, supporting a role of uPAR in pancreatic CSC biology as
well as the activity of the uPAR promoter in the PCSC
population.
Taken together, these results indicate that uPAR promoter is
active in pancreatic cancer stem cells and uPAR-controlled
oncolytic adenoviruses, on top of eliminating pancreatic
epithelial cancer cells, as we have previously reported (Huch
et al., 2009) are able to kill neoplastic cells with PCSC properties
in vitro. Moreover the antitumor effects of AduPARE1A and the
lack of enrichment in PCSC features of treated tumors support
the in vivo killing of pancreatic cancer stem cells.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.09.008.
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